Pasteur Institute: New Insights into Postpartum Breast Cancer Prevention

Cancer of the breast is a global health challenge, currently affecting nearly 12% of all cancer cases worldwide, according to the World Health Organization (WHO). It has become the most commonly diagnosed cancer globally and remains the leading cause of cancer-related deaths among women. Researchers at the Institut Pasteur in France are now investigating a potential pathway for preventing a particularly aggressive form of the disease: postpartum breast cancer.

A Focus on Postpartum Breast Cancer

Postpartum breast cancer is a form of the disease that develops within five to ten years after childbirth. It disproportionately affects younger women and is characterized by a three-fold increased risk of developing metastases and a poorer prognosis compared to breast cancers that arise at other times in a woman’s life. Approximately 5,000 women in France are diagnosed with this type of cancer annually, representing 50% of all breast cancer cases in women under 45.

The Changing Landscape of Childbearing

The average age of first-time mothers in France has increased to 29 years, five years later than in 1974. This shift is significant because the risk of developing postpartum breast cancer increases with maternal age, as pre-cancerous cells accumulate over a woman’s lifetime. A greater number of women may be affected by this type of cancer in the future.

The Role of ‘Phantom’ Cells

While breastfeeding offers a protective effect against breast cancer, studies over the past two decades have highlighted the postpartum period as a critical time of increased risk, particularly for women who give birth after age 35. This is when the mammary gland undergoes a process called ‘involuition’ – a period of regeneration and remodeling. During this process, certain cells, termed ‘phantom’ cells, stop multiplying but release molecules that interact with surrounding cells.

Research at the Institut Pasteur, published in Nature Aging, suggests these ‘phantom’ cells may contribute to an inflammatory environment that promotes tumor development. The molecules they produce appear to facilitate the spread of cancer cells, a mechanism that was previously not fully understood.

Potential Future Directions

In laboratory studies involving mice, researchers found that treatments aimed at eliminating these senescent, or ‘phantom,’ cells during the involution period significantly delayed tumor onset and reduced metastasis. However, these findings need to be confirmed in human tissues. A possible next step is identifying the specific molecules responsible for the increased aggressiveness of cancer cells, potentially allowing for their detection through a simple blood analysis.

Such a development could lead to improved monitoring of women at risk of postpartum breast cancer, especially those who have their first child after age 35 or have a genetic predisposition.

Frequently Asked Questions

What is postpartum breast cancer?

Postpartum breast cancer is a form of the disease diagnosed within five to ten years after a full-term pregnancy, with or without breastfeeding.

Why is postpartum breast cancer considered particularly aggressive?

Postpartum breast cancer carries a three times greater risk of developing metastases and a poorer prognosis compared to breast cancers that develop at other times in a woman’s life.

What are ‘phantom’ cells and how are they linked to cancer?

‘Phantom’ cells are cells that stop multiplying during the gland’s involution process but release molecules that may create an inflammatory environment and promote the spread of cancer cells.

As research continues, will a better understanding of the postpartum period lead to more effective prevention and treatment strategies for this challenging form of breast cancer?